retatrutide type 2 diabetes trial results Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 conducted in the USA π¨ Today, retatrutide, the GIP/GLP-1/glucagon
Pay in 4 interest-free payments of $5.74 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 28 - Sep 2
























